Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.

Paredes R, Schneider M, Stevens A, White DJ, K Williamson AJ, Muter J, Pearson S, Kelly JR, Connors K, Wiseman DH, Chadwick JA, Löffler H, Teng HY, Lovell S, Unwin R, van de Vrugt HJ, Smith H, Kustikova O, Schambach A, P Somervaille TC, Pierce A, Whetton AD, Meyer S.

Nucleic Acids Res. 2018 Aug 8. doi: 10.1093/nar/gky711. [Epub ahead of print] No abstract available.

PMID:
30102373
2.

Fluorescent genetic barcoding for cellular multiplex analyses.

Maetzig T, Morgan M, Schambach A.

Exp Hematol. 2018 Aug 8. pii: S0301-472X(18)30748-3. doi: 10.1016/j.exphem.2018.08.001. [Epub ahead of print] Review.

PMID:
30098396
3.

A patient-specific induced pluripotent stem cell model for West syndrome caused by ST3GAL3 deficiency.

van Diepen L, Buettner FFR, Hoffmann D, Thiesler CT, Halbach OVBU, Halbach VVBU, Jensen LR, Steinemann D, Edvardson S, Elpeleg O, Schambach A, Gerardy-Schahn R, Kuss AW.

Eur J Hum Genet. 2018 Aug 8. doi: 10.1038/s41431-018-0220-5. [Epub ahead of print]

PMID:
30089820
4.

Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model.

Salari A, Thomay K, Lentes J, Ebersold J, Hagedorn M, Skawran B, Davenport C, Schambach A, Schlegelberger B, Göhring G.

Oncotarget. 2018 Jul 6;9(52):29869-29876. doi: 10.18632/oncotarget.25581. eCollection 2018 Jul 6.

5.

EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.

Paredes R, Schneider M, Stevens A, White DJ, Williamson AJ, Muter J, Pearson S, Kelly JR, Connors K, Wiseman DH, Chadwick JA, Löffler H, Teng HY, Lovell S, Unwin R, van de Vrugt HJ, Smith H, Kustikova O, Schambach A, Somervaille TCP, Pierce A, Whetton AD, Meyer S.

Nucleic Acids Res. 2018 Jun 25. doi: 10.1093/nar/gky536. [Epub ahead of print]

PMID:
29939287
6.

Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.

Poletti V, Charrier S, Corre G, Gjata B, Vignaud A, Zhang F, Rothe M, Schambach A, Gaspar HB, Thrasher AJ, Mavilio F.

Mol Ther Methods Clin Dev. 2018 Mar 10;9:257-269. doi: 10.1016/j.omtm.2018.03.002. eCollection 2018 Jun 15.

7.

Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.

Brendel C, Rothe M, Santilli G, Charrier S, Stein S, Kunkel H, Abriss D, Müller-Kuller U, Gaspar B, Modlich U, Galy A, Schambach A, Thrasher AJ, Grez M.

Hum Gene Ther Clin Dev. 2018 Jun;29(2):69-79. doi: 10.1089/humc.2017.245. Epub 2018 Apr 17.

PMID:
29664709
8.

T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations.

Ghosh S, Carmo M, Calero-Garcia M, Ricciardelli I, Bustamante Ogando JC, Blundell MP, Schambach A, Ashton-Rickardt PG, Booth C, Ehl S, Lehmberg K, Thrasher AJ, Gaspar HB.

J Allergy Clin Immunol. 2018 Jan 31. pii: S0091-6749(18)30075-7. doi: 10.1016/j.jaci.2017.11.050. [Epub ahead of print]

9.

Pooled Generation of Lentiviral Tetracycline-Regulated microRNA Embedded Short Hairpin RNA Libraries.

Adams FF, Hoffmann T, Zuber J, Heckl D, Schambach A, Schwarzer A.

Hum Gene Ther Methods. 2018 Feb;29(1):16-29. doi: 10.1089/hgtb.2017.182.

PMID:
29325442
10.

Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells.

Pittermann E, Lachmann N, MacLean G, Emmrich S, Ackermann M, Göhring G, Schlegelberger B, Welte K, Schambach A, Heckl D, Orkin SH, Cantz T, Klusmann JH.

Blood Adv. 2017 Jun 2;1(14):903-914. doi: 10.1182/bloodadvances.2016003798. eCollection 2017 Jun 13.

11.

Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications.

Labuhn M, Adams FF, Ng M, Knoess S, Schambach A, Charpentier EM, Schwarzer A, Mateo JL, Klusmann JH, Heckl D.

Nucleic Acids Res. 2018 Feb 16;46(3):1375-1385. doi: 10.1093/nar/gkx1268.

12.

Impaired IFNγ-Signaling and Mycobacterial Clearance in IFNγR1-Deficient Human iPSC-Derived Macrophages.

Neehus AL, Lam J, Haake K, Merkert S, Schmidt N, Mucci A, Ackermann M, Schubert M, Happle C, Kühnel MP, Blank P, Philipp F, Goethe R, Jonigk D, Martin U, Kalinke U, Baumann U, Schambach A, Roesler J, Lachmann N.

Stem Cell Reports. 2018 Jan 9;10(1):7-16. doi: 10.1016/j.stemcr.2017.11.011. Epub 2017 Dec 14.

13.

Hematopoietic stem cell gene therapy for IFNγR1 deficiency protects mice from mycobacterial infections.

Hetzel M, Mucci A, Blank P, Nguyen AHH, Schiller J, Halle O, Kühnel MP, Billig S, Meineke R, Brand D, Herder V, Baumgärtner W, Bange FC, Goethe R, Jonigk D, Förster R, Gentner B, Casanova JL, Bustamante J, Schambach A, Kalinke U, Lachmann N.

Blood. 2018 Feb 1;131(5):533-545. doi: 10.1182/blood-2017-10-812859. Epub 2017 Dec 12.

PMID:
29233822
14.

Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy.

Biasco L, Rothe M, Büning H, Schambach A.

Mol Ther Methods Clin Dev. 2017 Oct 5;8:21-30. doi: 10.1016/j.omtm.2017.10.002. eCollection 2018 Mar 16. Review.

15.

Uncoupling the Oncogenic Engine.

Schambach A, Schott JW, Morgan MA.

Cancer Res. 2017 Nov 15;77(22):6060-6064. doi: 10.1158/0008-5472.CAN-17-2362. Epub 2017 Nov 2. Review.

PMID:
29097608
16.

Correction to: Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells.

Geis FK, Galla M, Hoffmann D, Kuehle J, Zychlinski D, Maetzig T, Schott JW, Schwarzer A, Goffinet C, Goff SP, Schambach A.

Retrovirology. 2017 Oct 18;14(1):48. doi: 10.1186/s12977-017-0372-3.

17.

An RNA-targeted therapy for dystrophic epidermolysis bullosa.

Peking P, Koller U, Duarte B, Murillas R, Wolf S, Maetzig T, Rothe M, Kocher T, García M, Brachtl G, Schambach A, Larcher F, Reichelt J, Bauer JW, Murauer EM.

Nucleic Acids Res. 2017 Sep 29;45(17):10259-10269. doi: 10.1093/nar/gkx669.

18.

Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis.

Biasco L, Rothe M, Schott JW, Schambach A.

Hematol Oncol Clin North Am. 2017 Oct;31(5):737-752. doi: 10.1016/j.hoc.2017.06.009. Review.

PMID:
28895844
19.

Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency.

Hetzel M, Suzuki T, Hashtchin AR, Arumugam P, Carey B, Schwabbauer M, Kuhn A, Meyer J, Schambach A, Van Der Loo J, Moritz T, Trapnell BC, Lachmann N.

Hum Gene Ther Methods. 2017 Dec;28(6):318-329. doi: 10.1089/hgtb.2017.092. Epub 2017 Aug 30.

PMID:
28854814
20.

Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.

Klapdor R, Wang S, Hacker U, Büning H, Morgan M, Dörk T, Hillemanns P, Schambach A.

Hum Gene Ther. 2017 Oct;28(10):886-896. doi: 10.1089/hum.2017.168. Epub 2017 Aug 24.

PMID:
28836469
21.

Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.

Klöß S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, Granzin M, Gardlowski T, Matthies N, Soltenborn S, Schambach A, Koehl U.

Hum Gene Ther. 2017 Oct;28(10):897-913. doi: 10.1089/hum.2017.157. Epub 2017 Aug 15.

PMID:
28810809
22.

The CpG-sites of the CBX3 ubiquitous chromatin opening element are critical structural determinants for the anti-silencing function.

Kunkiel J, Gödecke N, Ackermann M, Hoffmann D, Schambach A, Lachmann N, Wirth D, Moritz T.

Sci Rep. 2017 Aug 11;7(1):7919. doi: 10.1038/s41598-017-04212-8.

23.

The non-coding RNA landscape of human hematopoiesis and leukemia.

Schwarzer A, Emmrich S, Schmidt F, Beck D, Ng M, Reimer C, Adams FF, Grasedieck S, Witte D, Käbler S, Wong JWH, Shah A, Huang Y, Jammal R, Maroz A, Jongen-Lavrencic M, Schambach A, Kuchenbauer F, Pimanda JE, Reinhardt D, Heckl D, Klusmann JH.

Nat Commun. 2017 Aug 9;8(1):218. doi: 10.1038/s41467-017-00212-4.

24.

Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis.

Moscatelli I, Löfvall H, Schneider Thudium C, Rothe M, Montano C, Kertész Z, Sirin M, Schulz A, Schambach A, Henriksen K, Richter J.

Hum Gene Ther. 2018 Aug;29(8):938-949. doi: 10.1089/hum.2017.053. Epub 2017 Oct 3.

PMID:
28726516
25.

Multimodal Lentiviral Vectors for Pharmacologically Controlled Switching Between Constitutive Single Gene Expression and Tetracycline-Regulated Multiple Gene Collaboration.

Stahlhut M, Schambach A, Kustikova OS.

Hum Gene Ther Methods. 2017 Aug;28(4):191-204. doi: 10.1089/hgtb.2017.073. Epub 2017 Jul 5.

26.

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease.

Huang J, Khan A, Au BC, Barber DL, López-Vásquez L, Prokopishyn NL, Boutin M, Rothe M, Rip JW, Abaoui M, Nagree MS, Dworski S, Schambach A, Keating A, West ML, Klassen J, Turner PV, Sirrs S, Rupar CA, Auray-Blais C, Foley R, Medin JA.

Mol Ther Methods Clin Dev. 2017 May 12;5:241-258. doi: 10.1016/j.omtm.2017.05.003. eCollection 2017 Jun 16.

27.

An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries.

Adams FF, Heckl D, Hoffmann T, Talbot SR, Kloos A, Thol F, Heuser M, Zuber J, Schambach A, Schwarzer A.

Biomaterials. 2017 Sep;139:102-115. doi: 10.1016/j.biomaterials.2017.05.032. Epub 2017 May 23.

PMID:
28599149
28.

Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells.

Geis FK, Galla M, Hoffmann D, Kuehle J, Zychlinski D, Maetzig T, Schott JW, Schwarzer A, Goffinet C, Goff SP, Schambach A.

Retrovirology. 2017 May 31;14(1):34. doi: 10.1186/s12977-017-0358-1.

29.

Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.

Vink CA, Counsell JR, Perocheau DP, Karda R, Buckley SMK, Brugman MH, Galla M, Schambach A, McKay TR, Waddington SN, Howe SJ.

Mol Ther. 2017 Aug 2;25(8):1790-1804. doi: 10.1016/j.ymthe.2017.04.028. Epub 2017 May 24.

30.

Lentiviral Vectors with Cellular Promoters Correct Anemia and Lethal Bone Marrow Failure in a Mouse Model for Diamond-Blackfan Anemia.

Debnath S, Jaako P, Siva K, Rothe M, Chen J, Dahl M, Gaspar HB, Flygare J, Schambach A, Karlsson S.

Mol Ther. 2017 Aug 2;25(8):1805-1814. doi: 10.1016/j.ymthe.2017.04.002. Epub 2017 Apr 20.

31.

Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.

Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, von Hahn T.

J Hepatol. 2017 Aug;67(2):237-245. doi: 10.1016/j.jhep.2017.03.020. Epub 2017 Mar 29.

PMID:
28363797
32.

Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Hoffmann D, Schott JW, Geis FK, Lange L, Müller FJ, Lenz D, Zychlinski D, Steinemann D, Morgan M, Moritz T, Schambach A.

Gene Ther. 2017 May;24(5):298-307. doi: 10.1038/gt.2017.20. Epub 2017 Apr 20.

PMID:
28346436
33.

Inhibition of miRNA-212/132 improves the reprogramming of fibroblasts into induced pluripotent stem cells by de-repressing important epigenetic remodelling factors.

Pfaff N, Liebhaber S, Möbus S, Beh-Pajooh A, Fiedler J, Pfanne A, Schambach A, Thum T, Cantz T, Moritz T.

Stem Cell Res. 2017 Apr;20:70-75. doi: 10.1016/j.scr.2017.03.003. Epub 2017 Mar 7.

34.

A Lentiviral Fluorescent Genetic Barcoding System for Flow Cytometry-Based Multiplex Tracking.

Maetzig T, Ruschmann J, Lai CK, Ngom M, Imren S, Rosten P, Norddahl GL, von Krosigk N, Sanchez Milde L, May C, Selich A, Rothe M, Dhillon I, Schambach A, Humphries RK.

Mol Ther. 2017 Mar 1;25(3):606-620. doi: 10.1016/j.ymthe.2016.12.005. Epub 2017 Jan 5.

35.

Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors.

Ehrlich M, Mozafari S, Glatza M, Starost L, Velychko S, Hallmann AL, Cui QL, Schambach A, Kim KP, Bachelin C, Marteyn A, Hargus G, Johnson RM, Antel J, Sterneckert J, Zaehres H, Schöler HR, Baron-Van Evercooren A, Kuhlmann T.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2243-E2252. doi: 10.1073/pnas.1614412114. Epub 2017 Feb 28.

36.

Forced expression of human macrophage colony-stimulating factor in CD34+ cells promotes monocyte differentiation in vitro and in vivo but blunts osteoclastogenesis in vitro.

Montano Almendras CP, Thudium CS, Löfvall H, Moscatelli I, Schambach A, Henriksen K, Richter J.

Eur J Haematol. 2017 May;98(5):517-526. doi: 10.1111/ejh.12867. Epub 2017 Mar 6.

PMID:
28160330
37.

CSF-1-induced Src signaling can instruct monocytic lineage choice.

Endele M, Loeffler D, Kokkaliaris KD, Hilsenbeck O, Skylaki S, Hoppe PS, Schambach A, Stanley ER, Schroeder T.

Blood. 2017 Mar 23;129(12):1691-1701. doi: 10.1182/blood-2016-05-714329. Epub 2017 Feb 3.

38.

Retroviral Vectors for Cancer Gene Therapy.

Schambach A, Morgan M.

Recent Results Cancer Res. 2016;209:17-35. doi: 10.1007/978-3-319-42934-2_2. Review.

PMID:
28101685
39.

Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML.

Huang J, Liu Y, Au BC, Barber DL, Arruda A, Schambach A, Rothe M, Minden MD, Paige CJ, Medin JA.

Mol Ther Methods Clin Dev. 2016 Dec 7;3:16074. eCollection 2016.

40.

Improved bi-allelic modification of a transcriptionally silent locus in patient-derived iPSC by Cas9 nickase.

Eggenschwiler R, Moslem M, Fráguas MS, Galla M, Papp O, Naujock M, Fonfara I, Gensch I, Wähner A, Beh-Pajooh A, Mussolino C, Tauscher M, Steinemann D, Wegner F, Petri S, Schambach A, Charpentier E, Cathomen T, Cantz T.

Sci Rep. 2016 Dec 2;6:38198. doi: 10.1038/srep38198.

41.

Comparison of Tetracycline-regulated Promoters in Lentiviral-based Vectors in Murine Transplantation Studies.

Stahlhut M, Ha TC, Morgan M, Schambach A, Kustikova OS.

Curr Gene Ther. 2016;16(4):242-248. doi: 10.2174/1566523216666161013125215.

PMID:
27739375
42.

Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.

Punwani D, Kawahara M, Yu J, Sanford U, Roy S, Patel K, Carbonaro DA, Karlen AD, Khan S, Cornetta K, Rothe M, Schambach A, Kohn DB, Malech HL, McIvor RS, Puck JM, Cowan MJ.

Hum Gene Ther. 2017 Jan;28(1):112-124. doi: 10.1089/hum.2016.064. Epub 2016 Sep 7.

43.

Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency.

Mucci A, Kunkiel J, Suzuki T, Brennig S, Glage S, Kühnel MP, Ackermann M, Happle C, Kuhn A, Schambach A, Trapnell BC, Hansen G, Moritz T, Lachmann N.

Stem Cell Reports. 2016 Aug 9;7(2):292-305. doi: 10.1016/j.stemcr.2016.06.011. Epub 2016 Jul 21.

44.

Viral and Synthetic RNA Vector Technologies and Applications.

Schott JW, Morgan M, Galla M, Schambach A.

Mol Ther. 2016 Sep;24(9):1513-27. doi: 10.1038/mt.2016.143. Epub 2016 Jul 5. Review.

45.

Transduction of Murine Hematopoietic Stem Cells with Tetracycline-regulated Lentiviral Vectors.

Stahlhut M, Schambach A, Kustikova OS.

Methods Mol Biol. 2016;1448:65-76. doi: 10.1007/978-1-4939-3753-0_5.

PMID:
27317173
46.

Development of Inducible Molecular Switches Based on All-in-One Lentiviral Vectors Equipped with Drug Controlled FLP Recombinase.

Maetzig T, Schambach A.

Methods Mol Biol. 2016;1448:23-39. doi: 10.1007/978-1-4939-3753-0_2.

PMID:
27317170
47.

Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions.

Börger AK, Eicke D, Wolf C, Gras C, Aufderbeck S, Schulze K, Engels L, Eiz-Vesper B, Schambach A, Guzman CA, Lachmann N, Moritz T, Martin U, Blasczyk R, Figueiredo C.

Mol Med. 2016 May 16;22. doi: 10.2119/molmed.2015.00235. [Epub ahead of print]

48.

Establishing a murine xenograft-model for long-term analysis of factors inducing chromosomal instability in myelodysplastic syndrome: Pitfalls and successes.

Salari A, Thomay K, Himmler K, Vajen B, Schienke A, Hagedorn M, Ebersold J, Kreipe HH, Krüger A, Schambach A, Schlegelberger B, Göhring G.

Cancer Genet. 2016 Jun;209(6):258-66. doi: 10.1016/j.cancergen.2016.04.004. Epub 2016 Apr 22.

PMID:
27184732
49.

Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes.

Labenski V, Suerth JD, Barczak E, Heckl D, Levy C, Bernadin O, Charpentier E, Williams DA, Fehse B, Verhoeyen E, Schambach A.

Biomaterials. 2016 Aug;97:97-109. doi: 10.1016/j.biomaterials.2016.04.019. Epub 2016 Apr 26.

PMID:
27162078
50.

Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform.

Hübner J, Hoseini SS, Suerth JD, Hoffmann D, Maluski M, Herbst J, Maul H, Ghosh A, Eiz-Vesper B, Yuan Q, Ott M, Heuser M, Schambach A, Sauer MG.

Mol Ther. 2016 Aug;24(7):1216-26. doi: 10.1038/mt.2016.89. Epub 2016 May 3.

Supplemental Content

Loading ...
Support Center